Revenue
2020
2021
2022
2023
2024
2025
TScan Therapeutics, Inc. (TCRX)
Price$0.3919Cached quote
Net income
2020
2021
2022
2023
2024
2025
Free cash flow
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Revenue | $10.3M | $2.8M | $21.0M | $13.5M | $10.1M | $1.1M |
| Research & development | $114.2M | $107.3M | $88.2M | $59.8M | $45.0M | $20.6M |
| Operating expenses | $146.1M | $137.6M | $114.5M | $80.2M | $58.8M | $27.3M |
| Operating income | −$135.8M | −$134.8M | −$93.5M | −$66.6M | −$48.6M | −$26.2M |
| Operating margin | −1,315.38% | −4,787.68% | −444.00% | −492.32% | −479.65% | −2,417.79% |
| EBITDA | −$132.9M | −$130.7M | −$88.1M | −$61.5M | −$45.3M | −$25.0M |
| EBITDA margin | −1,287.29% | −4,642.08% | −418.35% | −454.64% | −447.11% | −2,307.19% |
| Net income | −$129.8M | −$127.5M | −$89.2M | −$66.2M | −$48.6M | −$26.1M |
| Net profit margin | −1,256.81% | −4,527.66% | −423.86% | −489.26% | −479.49% | −2,408.02% |
| Basic EPSper basic share | -$1.00 | -$1.14 | -$1.36 | -$2.75 | -$4.17 | -$28.52 |
| Diluted EPSper diluted share | -$1.00 | -$1.14 | -$1.36 | -$2.75 | -$4.17 | -$28.52 |
Owners
Reported shareholders
12.63%of listed shares
Lynx1 Capital Management LP8.02M shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
Lynx1 Capital Management LP | 12.63%8.02M shares |
BVF INC/IL | 8.76%5.56M shares |
BAKER BROS. ADVISORS LP | 4.39%2.78M shares |
VANGUARD CAPITAL MANAGEMENT LLC | 3.40%2.16M shares |
TWO SIGMA INVESTMENTS, LP | 3.07%1.95M shares |
RENAISSANCE TECHNOLOGIES LLC | 2.09%1.33M shares |
ACADIAN ASSET MANAGEMENT LLC | 2.06%1.31M shares |
Deer Management Co. LLC | 1.96%1.25M shares |
MILLENNIUM MANAGEMENT LLC | 1.83%1.16M shares |
JACOBS LEVY EQUITY MANAGEMENT, INC | 1.65%1.05M shares |
CITADEL ADVISORS LLC | 1.59%1.01M shares |
BlackRock, Inc. | 1.57%994.65K shares |
Kalehua Capital Management LLC | 1.43%909.75K shares |
BOOTHBAY FUND MANAGEMENT, LLC | 1.22%772.24K shares |
MARSHALL WACE, LLP | 1.08%687.36K shares |
DC Funds, LP | 0.99%630K shares |
GEODE CAPITAL MANAGEMENT, LLC | 0.92%584.81K shares |
D. E. Shaw & Co., Inc. | 0.86%548.4K shares |
GSA CAPITAL PARTNERS LLP | 0.86%548.09K shares |
VANGUARD FIDUCIARY TRUST CO | 0.57%363.95K shares |
Percentages use 63.5M shares of this listed class outstanding on Jun 30, 2026.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Dec 23, 2025Form 4 | Lynx1 Capital Management LP +1TenPercentOwner | BuyCommon Stock · indirect | 6.2K | $0.90 | $5.6K | 8.02M |
| Dec 22, 2025Form 4 | Lynx1 Capital Management LP +1TenPercentOwner | BuyCommon Stock · indirect | 75.5K | $0.90 | $68.0K | 8.01M |
| Dec 19, 2025Form 4 | Lynx1 Capital Management LP +1TenPercentOwner | BuyCommon stock, $0.0001 par value per share ("Common Stock") · indirect | 80.1K | $0.90 | $72.1K | 7.94M |
| May 20, 2025Form 4 | Lynx1 Capital Management LP +1TenPercentOwner | BuyCommon Stock · indirect | 1.20M | $1.20 | $1.44M | 7.95M |
| May 19, 2025Form 4 | Lynx1 Capital Management LP +1TenPercentOwner | BuyCommon stock, $0.0001 par value per share ("Common Stock") · indirect | 1.39M | $1.20 | $1.67M | 6.75M |